Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6976 to 6990 of 7679 results

  1. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    In development [GID-TA11024] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued [GID-TA10963]

    Technology appraisal guidance
    Discontinued

  3. Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

    Discontinued [GID-TA10811]

    Technology appraisal guidance
    Discontinued

  4. Housing: planning to improve health and wellbeing

    Discontinued [GID-NG10053]

    NICE guideline
    Discontinued

  5. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development [GID-TA10489] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued [GID-TA10495]

    Technology appraisal guidance
    Discontinued

  7. Workplace health - older employees

    Discontinued [GID-PHG59]

    NICE guideline
    Discontinued

  8. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued [GID-MT536]

    Medical technologies guidance
    Discontinued

  9. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development [GID-TA10261] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]

    Technology appraisal guidance
    Discontinued

  11. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued [GID-TAG369]

    Technology appraisal guidance
    Discontinued

  12. Phentermine with topiramate for the treatment of obesity and overweight [ID543]

    Discontinued [GID-TAG439]

    Technology appraisal guidance
    Discontinued

  13. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued [GID-TAG321]

    Technology appraisal guidance
    Discontinued

  14. Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

    Discontinued [GID-TA10177]

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued [GID-TA10271]

    Technology appraisal guidance
    Discontinued